DRUG-INDUCED RHINITIS: QUESTIONS AND ANSWERS
https://doi.org/10.21518/2079-701X-2017-8-112-115
Abstract
Drug-induced rhinitis (DIR) develops as a result of long-term use of topical decongestants and different drugs of systemic action. The article presents a review of the literature covering the issues of pathogenesis, clinic, diagnostics and treatment of the disease. It is stressed that currently intranasal glucocorticosteroids are the only drugs effectiveness of which for drug-induced rhinitis is proved in randomized controlled clinical trials. The authors provide observations of the use of mometasone furoate in 16 patients with DIR for 4 weeks at a dosing of 400 mg/day. 12 patients (75%) were able to completely stop taking decongestants to the end of the second week of treatment. In one case there was recurrence of the disease.
Topical steroids help to alleviate the patient’s period of withdrawal from topical vasoconstrictor preparations. However, patients should be warned about the possibility of recurrence of DIR in cases of repeated uncontrolled use of decongestants.
References
1. Baldwin RL. Rhinitis medicamentosa (an approach to treatment). J Med Assoc State Ala, 1975, 47: 33-35.
2. Fox N. Chronic effect of epinephrine and ephedrine on the nasal mucosa. Arch Otolaryngol, 1931, 30: 73-76.
3. Feinberg SM, Friedlaender S. Nasal congestion from frequent use of privine hydrochloride. J Am Med Assoc, 1945, 128: 1095-1096. doi:10.1001/jama.1945.92860320001011.
4. Lake CF. Rhinitis medicamentosa. Proc Staff Meet Mayo Clin, 1946, 21: 367-71.
5. Mortuairea G, de Gaboryb L, Francёois M, Massйd G, Bloche F, Brionf N, Jankowskig R, Serranoh E. Rebound congestion and rhinitis medicamentosa: Nasal decongestants in clinical practice. Critical review of the literature by a medical panel. European Annals of Otorhinolaryngology, Head and Neck diseases, 2013, 130: 137-144. doi: 10.1016/j.anorl.2012.09.005.
6. Graf PM, Hallen H. Changes in nasal reactivity in patients with rhinitis medicamentosa after treatment with fluticasone propionate and placebo nasal spray. ORL J Otorhinolaryngol Relat Spe, 1998, 60: 334-338.
7. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med, 2005, 4: 21-29.
8. Passali D, Salerni L, Passali GC, Passali FM, Bellussi L. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf, 2006, 5: 783-790. doi: 10.1517/14740338.5.6.783.
9. Lockey RF. Rhinitis medicamentosa and the stuffy nose. J Allergy Clin Immunol, 2006, 118: 1017-1018. doi:10.1016/j.jaci.2006.06.018.
10. Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazolineinduced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med, 2010, 182(1): 19-24. doi: 10.1164/rccm.200911-1701OC.
11. Graf P. Long-term use of oxyand xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology,1996, 34: 9-13.
12. Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy, 1997, 52(40): 28-34.
13. Лопатин А.С. Сосудосуживающие препараты: механизмы действия, клиническое применение и побочные эффекты. Российская ринология, 2007, 1: 43-48.
14. Лопатин А.С. Ринит. Руководство для врачей. М.: Литтерра, 2010: 417.
15. Morris S, Eccles R, Martez SJ, Riker DK, Witek TJ. An evaluation of nasal response following different treatment regimens of oxymetazoline with references to rebound congestion. Am J Rhinol, 1997, 11: 109-115.
16. Yoo JK, Seikaly H, Calhoun KH. Extended use of topical nasal decongestants. Laryngoscope, 1997, 107: 40-43.
17. Watanabe H, Foo TH, Djazeri B. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology, 2003, 41: 167-174.
18. Lin CY, Cheng PH, Fang SY. Mucosal changes in rhinitis medicamentosa. Ann Otol Rhinol Laryngol, 2004, 113: 47-51.
19. Knipping S, Holzhausen HJ, Goetze G, Riederer A, Bloching MB. Rhinitis medicamentosa: electron microscopic changes of human nasal mucosa. Otolaryngol Head Neck Surg, 2007, 136: 57-61. doi:10.1016/j.otohns.2006.08.025.
20. Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol, 2006, 16(3): 148-155.
21. Walker JS. Rhinitis medicamentosa. J Allergy, 1952, 23(2): 183-186.
22. Stephens AL, Boggs PB. Intranasal dexamethasone: an adjunct in the treatment of chemical rhinitis. Ann Allergy, 1968, 26: 612-613.
23. Hallen H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin. Ex Allergy, 1997, 27: 552-558.
24. Tas A, Yagiz R, Yalcin O, Uzun C, Huseyinova G, Adali MK, Karasalihoglu AR. Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study. Otolaryngol Head Neck Surg, 2005, 132(4): 608-612. doi: 10.1016/j.otohns.2005.01.010.
25. Minshall E, Ghaffar O, Cameron L, O’Brien F, Quinn H, Rowe-Jones J, Davies RJ, Prior A, Lund VJ, Mackay IS, Nolop K, Lutsky B, Durham SR, Hamid Q. Assessment by nasal biopsy of long-term of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg, 1998, 118(5): 648-654.
26. Yuta A, Ogawa Y. Clinical review of 33 cases of rhinitis medicamentosa by decongestant nasal spray. Arerugi, 2013, 62(12): 1623-1630.
Review
For citations:
Shelenkova VV. DRUG-INDUCED RHINITIS: QUESTIONS AND ANSWERS. Meditsinskiy sovet = Medical Council. 2017;(8):112-115. (In Russ.) https://doi.org/10.21518/2079-701X-2017-8-112-115
Views:
754
Email this article 